News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

February 26, 2020 Apellis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference
January 13, 2020 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
January 8, 2020 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 7, 2020 Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 7, 2020 Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
January 2, 2020 Apellis Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
November 26, 2019 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 15, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 8, 2019 Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week
November 7, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)